May 23, 2022 10:44 AM EDTUpdated 12:36 PM

A cell therapy biotech finds a delivery partner; FDA removes clinical hold on Ocugen's Covid candidate

Kyle LaHucik

Senior Reporter

Tyler Patchen

News Reporter

Umoja Biopharma will pair its so-called VivoVec particles with Lupagen’s Side CAR-T delivery system to target certain cancers, the companies said Monday.

As part of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A cell therapy biotech finds a delivery partner; FDA removes clinical hold on Ocugen's Covid candidate

Kyle LaHucik

Senior Reporter

Tyler Patchen

News Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

A cell ther­a­py biotech finds a de­liv­ery part­ner; FDA re­moves clin­i­cal hold on Ocu­gen's Covid can­di­date

Senior Reporter

News Reporter

Sign up to read this article for free.

A cell therapy biotech finds a delivery partner; FDA removes clinical hold on Ocugen's Covid candidate